MRNA Technical Analysis
As of date:6/28/2022
MRNA stock price:142.19
MRNA 50 DMA:138.72
MRNA 200 DMA:218.10
MRNA MACD (200-50):79.38
MRNA RSI:48.05
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)48.05
Extremely
Oversold

Also see:
MRNA Market Cap History
MRNA Shares Outstanding History
MRNA YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes

Email EnvelopeFree MRNA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

WEYS Crosses Below Key Moving Average Level
1 hour, 28 minutes ago


REPX Crosses Below Key Moving Average Level
1 hour, 43 minutes ago


IVT Makes Notable Cross Below Critical Moving Average
1 hour, 43 minutes ago


Enphase Energy (ENPH) Shares Cross Below 200 DMA
6 hours, 23 minutes ago


Notable Two Hundred Day Moving Average Cross - CRZBF
6 hours, 34 minutes ago


EFN.CA Crosses Below Key Moving Average Level
7 hours, 12 minutes ago


ULTA Makes Notable Cross Below Critical Moving Average
Tuesday, June 28, 4:25 PM


Landec Breaks Below 200-Day Moving Average - Notable for LNDC
Tuesday, June 28, 4:24 PM


CVG.CA Crosses Above Key Moving Average Level
Tuesday, June 28, 3:42 PM


TCOM Crosses Above Key Moving Average Level
Tuesday, June 28, 12:35 PM


Notable Two Hundred Day Moving Average Cross - SHEN
Tuesday, June 28, 12:35 PM


Republic Bancorp Breaks Above 200-Day Moving Average - Bullish for RBCAA
Tuesday, June 28, 12:32 PM


Bullish Two Hundred Day Moving Average Cross - CHMG
Tuesday, June 28, 12:31 PM


China Eastern Airlines (CEA) Shares Cross Above 200 DMA
Tuesday, June 28, 11:01 AM


National Retail Properties (NNN) Shares Cross Above 200 DMA
Tuesday, June 28, 10:59 AM


More Technical Analysis News

MRNA Technical AnalysisMRNA RSI
Moderna is a biotechnology company creating medicines based on messenger RNA (mRNA) to improve the lives of patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Co.'s platform builds on basic and applied mRNA science, delivery technology, and manufacturing, providing it the capability to pursue in parallel a pipeline of new development candidates. Co. is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.

When researching a stock like Moderna, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from MRNA Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for MRNA stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
MRNA DMAMRNA MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Moderna (MRNA) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

OGN Technical Analysis
PFE Technical Analysis
PKI Technical Analysis
REGN Technical Analysis
RMD Technical Analysis
STE Technical Analysis
SYK Technical Analysis
TECH Technical Analysis
TFX Technical Analysis
TMO Technical Analysis
More Healthcare companies »

 

MRNA Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.